Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: A phase II study

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1727-1731

  Brandes, A A ^a   Basso, U ^a   Vastola, F ^a   Tosoni, A ^a   Pasetto, L M ^a   Jirillo, A ^a   Lonardi, S ^a   Paris, M K ^a   Koussis, H ^a   Monfardini, S ^a   Ermani, M ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Carboplatin; Chemotherapy; Oligodendroglioma; Salvage therapy; Teniposide

Indexed keywords

ANTICONVULSIVE AGENT; CARBOPLATIN; CORTICOSTEROID; ETOPOSIDE; LOMUSTINE; PROCARBAZINE; SEROTONIN ANTAGONIST; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOXICITY; FEMALE; HUMAN; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUTROPENIA; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OLIGODENDROGLIOMA; SURVIVAL ANALYSIS; TENIPOSIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 9144235879     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg494     Document Type: Article

References (23)

1. Brandes AA, Fiorentino MV. Clinical, pathological and therapeutic aspects of oligodendroglioma. Cancer Treat Rev 1998; 2: 101 -111.
2. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 10: 2013-2021.
3. van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998; 4: 1140-1145.
4. van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001; 2: 340-342.
5. Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2000; 19: 2449-2455.
6. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9: 860-864.
7. Friedman HS, Lovel S, Rasheed K. Treatment of adults with progressive oligodendroglioma with carboplatin: preliminary results. Med Ped Oncol 1998; 31: 16-18.
8. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673-679.
9. Spremulli E, Schulz JJ, Speckart VJ. Phase II study of VM-26 in adult malignancies. Cancer Treat Rep 1980; 64: 147-150.
10. Brandes AA, Rigon A, Zampieri P et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 1998; 82: 355-361.
11. Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992; 10: 1074-1077.
12. Kleihues P, Louis DN, Scheithauer BW et al. WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 3: 215-225.
13. World Health Organization. WHO Handbook for reporting results of cancer treatment (WHO offset Publications no. 48). Neoplasma 1980; 20: 37-46.
14. Baker DK, Relling MV, Pui CH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-315.
15. Macdonald DR, Cascino TL, Clifford S et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
17. Peterson K, Paleologos N, Forsyth P. Salvage chemotherapy for anaplastic oligodendrogliomas. J Neurosurg 1996; 85: 597-601.
18. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendroglioma. J Clin Oncol 1997; 15: 3427-3432.
19. Kim L, Hochberg FH, Thornton AF et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996; 4: 602-607.
20. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-645.
21. Grossman SA, Hochberg F, Fisher J et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998; 2: 118-126.
22. Jakacki RI, Siffert J, Jamison C et al. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J Neurooncol 1999; 1: 77-83.
23. Cairncross G, Swinnen L, Bayer R et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Oligodendroglioma Study Group. Neuro-oncol 2000; 2: 114-119.